Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients | NCT00288951 | Trialant
CompletedInterventionalPhase 3Updated Aug 17, 2012
Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
ClinicalTrials.gov ID
NCT00288951
Lead Sponsor
Alcon ResearchINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
690Actual
Last Update Posted
Aug 17, 2012Estimated
Start Date
Oct 2004
Primary Completion Date
Jun 2005Actual
Completion Date
Jun 2005Actual
Brief Summary
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
Open-angle Glaucoma
Ocular Hypertension
Travoprost 0.004% with and without BAK
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult subjects of either sex and any race 18 years or older with open-angle glaucoma or ocular hypertension. Patients with logMAR visual acuity not worse than 0.6 in either eye or any clinically relevant ophthalmic/systemic condition will be excluded.